Skip to main content

Table 3 Adverse events ≥grade 3 in the SOX arm (n=53)

From: Randomized phase II study comparing the efficacy and safety of SOX versus mFOLFOX6 as neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer (KSCC1301)

  All grades Grade 3–4
n (%) n (%)
Laboratory findings
 Thrombocytopenia 49 (92.5) 10 (18.9)
 Neutropenia 42 (79.2) 7 (13.2)
 Anemia 47 (88.7) 1 (1.9)
 Hypoalbuminemia 46 (86.8) 1 (1.9)
 Increased AST 42 (79.2) 1 (1.9)
 Hyponatremia 23 (43.4) 1 (1.9)
Clinical findings
 Anorexia 25 (47.2) 2 (3.8)
 Paresthesia 36 (67.9) 1 (1.9)
 Fatigue/malaise 21 (39.6) 1 (1.9)
  1. AST: aspartate aminotransferase, SOX: S-1 and oxaliplatin